See How They LIE!

See How They LIE! A closer look at The 2 Major Laetrile Studies

This section looks at the two major studies conducted on Laetrile.

1. One study in 1982 by Dr. Charles Moertel, of the Mayo Clinic. - A clinical trial of amygdalin (Laetrile) in the treatment of human cancer. N Engl J Med 1982: 306 (4): 201-6.
2. The other by: Ellison N, Bvar D, Newell G. "Special report on Laetrile: The NCI Laetrile Review N Engl J Med 1978: 299 (10): 549-552.

Before we begin, I would like to also mention Dr Dean Burk (1904-1988) who worked 34 years with the National Cancer Institute and was one of the Co-Founders of the NCI. He experienced the laetrile controversy first hand. He witnessed and wrote about the credibility of these studies against laetrile which the entire medical profession today refer to and quote when Laetrile is mentioned.

"They (ACS) lie like scoundrels."----Dean Burk, Ph.D., 34 years at the National Cancer Institute
(Peter Barry Chowka, "The Cancer Charity Rip-Off," East West Journal, July 1978)

 

I (The author of this website) wish to thank Dr Stephen Krashen Ph.D. from the University of California for providing/publishing two current papers (2009) which examined each of the two studies mentioned above against laetrile and concluded the findings from both studies were inaccurate and not conducted properly.

In essence the 2 major clinical studies on Laetrile were studies that were designed to fail.

The two studies can be downloaded here (Right mouse click - select Save AS)

Keep in mind the same doctors that originally claimed laetrile did not work and stamped it out in the 50's have become infamous for defending smoking as not related to lung cancer, but more importantly, the infamous quote by Dr MacDonald "a pack a day keeps lung cancer away" - click here for info - Not surprisingly it was later found that they were paid off by the tobacco companies to report smoking as not related to lung cancer. Hmmm.... I wonder if they were paid off by Chemical companies that make Chemo drugs to report the false results as they did?

More Lies:

Dr. Schmidt, FDA Commissioner, as cited on about March 25, 1974…"Every study to date has not found any evidence of efficacy" with laetrile, and "if there was one shred of evidence from animal or cell systems I would issue an IND" (Investigational New Drug status that approves clinical testing in humans).

Mr. Robert Wetherell, Acting Director, Office of Legislative Services, FDA, "No evidence of antitumour activity has been found in any of the tests" with Laetrile, in current issued status report.

Dr. Frank Rauscher, Director, NCI, "I would certainly not turn off Laetrile if it had an iota of activity that we could pinpoint. Unfortunately, there is no evidence at all," stated on March 312, 1974 on the Mike Wallace 60 Minutes CBS Show.

Dr. Robert Hadsell, Officer of Cancer Communications, NCI, "All testing by NCI has found no evidence of activity against cancer" by laetrile, in letters sent throughout the US and abroad.

Dr. Jesse Steinfeld, former Surgeon General of the USHS, Laetrile "has repeatedly been tested in animal tumour systems at the NCI. In no instance did laetrile have activity in any animal tumour system. There is no basis for the use of laetrile in man based on the data derived from experiments in animals," in an interoffice memo sent to Dept Heads of the Mayo Clinic, jan 1974.

Dr. Charles Moertel, of the Mayo Clinic, "Extensive animal tumour studies conducted independently at two outstanding cancer research centres—New York memorial Sloan Kettering (MSK) and the Southern Research Institute-—have shown this drug to be totally without evidence of anticancer activity." In a letter published in the Rochester (Minn.) Post Bulletin, Jan 21 1974.

MORE TRUTH:

The facts are, as partially detailed in the letter of March 22, 1974 from Dean Burk to Seymour Perry, that positive, statistically highly significant, anticancer activity by Laetrile in animal tumour systems has been observed in at least 5 independent institutions in 3 widely separated countries of the world, with a variety of animal cancers;

1). Southern Research Institute (Birmingham Alabama), for the NCI, in a majority of 280 BDF1 mice bearing Lewis lung cancers, treated with up to 400 mg Laetrile (Amygdalin MF) per kg body weight, with respect to increased median life span (Dec 3, 1973).

2). Sloan Kettering (New York) with CD8 F1 mice bearing spontaneous mammary carcinomas, inhibition of formation of lung metastases, inhibition of growth of primary tumours, and greater health and appearance of animal hosts, upon treatment with 1-2 gm Laetrile/per kg body weight/day. (June 13, 1973)

3). Scind Laboratories, University of San Francisco, 400 rats bearing Walker 256 carcinoma (200 treated with Amygdalin, 200 controls), with 80% increase in life span at optimum dosage (500 mg Amgdalin/kg body weight). (Oct 10, 1968) Cf. FDA-IND 6734 application, pp. 247-248, 00080-00093. NCI Director Carl Baker wrote Congressman Edwin W. Edwards on Jan 26, 1971: "The data provided by the McNaughton Foundation certainly indicates some activity in animal tumour systems" (emphasis added).

4). Pasteur Institute (Paris), with human cancer strain maintained in mice, treated at optimal dosage og 500 mg Amygdalin Marsan/kg body weight/day, increased life span and delayed tumour growth up to 100% (Dec 6, 1971).

5). Institute von ardenne (Dresden, Germnay), H strain mice bearing Ehrlich ascites carcinoma treated with bitter almond amygdalin ad libitum in addition to regular chow diet, yielded increased life span and decreased rate of cancer growth, treatment beginning 15 days before cancer inoculation (arch. Geschwulstorsch. 42, 135-7 (1973).

No iota of activity, no shred of evidence? It will be interesting to see if FDA Commissioner Schmidt will indeed soon back up his word about issuing a Laetrile IND, a form of FDA approval, incidently, requiring no prior human data.